Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis. by Bustos, Matias et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
6-25-2020 
Integrated Assessment of Circulating Cell-Free MicroRNA 
Signatures in Plasma of Patients with Melanoma Brain 
Metastasis. 
Matias Bustos 
Division of Molecular Oncology, Department of Translational Molecular Medicine, John Wayne Cancer 
Institute at Providence Saint John's Health Center, Santa Monica, California. 
Kevin Tran 
Division of Molecular Oncology, Department of Translational Molecular Medicine, John Wayne Cancer 
Institute at Providence Saint John's Health Center, Santa Monica, California. 
Negin Rahimzadeh 
Department of Translational Molecular Medicine, John Wayne Cancer Institute at Providence Saint John's 
Health Center, Santa Monica, CA 90404, USA. 
Rebecca Gross 
Department of Translational Molecular Medicine, John Wayne Cancer Institute at Providence Saint John's 
Health Center, Santa Monica, CA 90404, USA. 
Selena Y Lin 
Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USA 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Neurosciences Commons, and the Oncology Commons 
Recommended Citation 
Bustos, Matias; Tran, Kevin; Rahimzadeh, Negin; Gross, Rebecca; Lin, Selena Y; Shoji, Yoshiaki; Murakami, 
Tomohiro; Boley, Christine L; Tran, Linh T; Cole, Hunter; Kelly, Daniel F; O'Day, Steven J; and Hoon, Dave, 
"Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with 
Melanoma Brain Metastasis." (2020). Articles, Abstracts, and Reports. 3365. 
https://digitalcommons.psjhealth.org/publications/3365 
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has 
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. 
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org. 
Authors 
Matias Bustos, Kevin Tran, Negin Rahimzadeh, Rebecca Gross, Selena Y Lin, Yoshiaki Shoji, Tomohiro 
Murakami, Christine L Boley, Linh T Tran, Hunter Cole, Daniel F Kelly, Steven J O'Day, and Dave Hoon 




Integrated Assessment of Circulating Cell-Free
MicroRNA Signatures in Plasma of Patients with
Melanoma Brain Metastasis
Matias A. Bustos 1 , Kevin D. Tran 2, Negin Rahimzadeh 1 , Rebecca Gross 1 , Selena Y. Lin 1,
Yoshiaki Shoji 1 , Tomohiro Murakami 1, Christine L. Boley 3, Linh T. Tran 2, Hunter Cole 3,
Daniel F. Kelly 4, Steven O’Day 3 and Dave S. B. Hoon 1,2,*
1 Department of Translational Molecular Medicine, John Wayne Cancer Institute at Providence Saint John’s
Health Center, Santa Monica, CA 90404, USA; Bustosm@jwci.org (M.A.B.);
Negin.Rahimzadeh@providence.org (N.R.); Rebecca.Gentry@providence.org (R.G.);
Selena.Lin@providence.org (S.Y.L.); Yoshiaki.Shoji@providence.org (Y.S.);
Tomohiro.Murakami@providence.org (T.M.)
2 Department of Genomic Sequencing Center, John Wayne Cancer Institute at Providence Saint John’s Health
Center, Santa Monica, CA 90404, USA; Kevin.Tran@providence.org (K.D.T.);
linh.tran3@providence.org (L.T.T.)
3 Department of Immuno-Oncology and Clinical Research, John Wayne Cancer Institute,
Santa Monica, CA 90404, USA; christine.boley@providence.org (C.L.B.);
Hunter.Cole@providence.org (H.C.); O’DayS@jwci.org (S.O.D.)
4 Pacific Neuroscience Institute, John Wayne Cancer Institute, Saint John’s Health Center,
Santa Monica, CA 90404, USA; kellyd@jwci.org
* Correspondence: hoond@jwci.org
Received: 4 May 2020; Accepted: 23 June 2020; Published: 25 June 2020


Abstract: Primary cutaneous melanoma frequently metastasizes to distant organs including the brain.
Identification of cell-free microRNAs (cfmiRs) found in the blood can be used as potential body fluid
biomarkers for detecting and monitoring patients with melanoma brain metastasis (MBM). In this
pilot study, we initially aimed to identify cfmiRs in the blood of MBM patients. Normal donors
plasma (healthy, n = 48) and pre-operative MBM patients’ plasma samples (n = 36) were compared for
differences in >2000 microRNAs (miRs) using a next generation sequencing (NGS) probe-based assay.
A 74 cfmiR signature was identified in an initial cohort of MBM plasma samples and then verified in a
second cohort of MBM plasma samples (n = 24). Of these, only 58 cfmiRs were also detected in MBM
tissues (n = 24). CfmiR signatures were also found in patients who have lung and breast cancer brain
metastasis (n = 13) and glioblastomas (n = 36) compared to MBM plasma samples. The 74 cfmiR
signature and the latter cfmiR signatures were then compared. We found a 6 cfmiR signature that was
commonly upregulated in MBM plasma samples in all of the comparisons, and a 29 cfmiR signature
that distinguishes MBM patients from normal donors’ samples. In addition, we assessed for cfmiRs
in plasma (n = 20) and urine (n = 14) samples collected from metastatic melanoma patients receiving
checkpoint inhibitor immunotherapy (CII). Pre- and post-treatment samples showed consistent
changes in cfmiRs. Analysis of pre- and post-treatment plasma samples showed 8 differentially
expressed (DE) cfmiRs that overlapped with the 35 cfmiR signature found in MBM patients. In paired
pre-treatment plasma and urine samples receiving CII 8 cfmiRs overlapped. This study identified
specific cfmiRs in MBM plasma samples that may potentially allow for assessment of melanoma
patients developing MBM. The cfmiR signatures identified in both blood and urine may have
potential utility to assess CII responses after further validation.
Cancers 2020, 12, 1692; doi:10.3390/cancers12061692 www.mdpi.com/journal/cancers
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1. Introduction
Cutaneous melanoma is one of the most aggressive metastatic solid tumors, with an increasing
incidence over the last decade [1]. Metastatic melanoma is difficult to manage because of its rapid growth
and propensity to spread to distant organs such as the liver, lung, and brain [2]. Melanoma has the third
highest incidence of brain metastasis of extracranial origin tumors after lung and breast cancers [3].
Melanoma brain metastasis (MBM) can be lethally aggressive although often remains dormant in
early stages and clinically undetectable [4]. New effective checkpoint inhibitor immunotherapies (CII)
have significantly improved survival outcomes for metastatic melanoma patients [5,6]; however, early
detection of MBMs remain a key factor for the implementation of treatment regimens such as: targeted
therapy, CII, radiological, and surgical interventions [5,7]. Also, there is still an issue when evaluating
which metastatic patients will benefit from specific therapies [8]. Moreover, there is a lack of blood
biomarkers available to monitor metastatic melanoma patients undergoing treatment. Until now,
elevated serum lactate dehydrogenase (sLDH) levels are the only validated independent diagnostic
blood biomarker for the American Joint Committee on Cancer (AJCC) stage IV melanoma patients,
but often sLDH does not translate into meaningful clinical information that can be used for deciding
patients’ therapeutic treatments [9,10].
Blood and urine biomarkers such as cell-free nucleic acids (cfNA) are among the most practical,
cost-effective, and minimally invasive approaches that allow for easier compliance and participation
by patients [11,12]. As biomarkers, cfNA have limitations in solid tumor patients such as: (1) Detection
efficacy as related to the tumor burden, (2) amount of specific tumor cfNA that are detectable in the
volume sampled, (3) profiling large numbers of cfNA at one time, and (4) degradation of cfNA [13,14].
Detection of metastatic melanoma has improved in recent years, particularly using circulating cell-free
DNA (cfDNA) analysis targeting specific mutations [15–19]. Nonetheless, detection of metastatic
cutaneous melanomas has been difficult due to a limited number of frequent mutations that are
observed at specific gene exon sites, other than BRAF (<60%) and NRAS (<25%) genes, thus reducing
the sensitivity of melanoma detection in blood. Moreover, cfDNA is unstable in body fluids and has
a short half-life [20,21].
On the contrary, microRNAs (miRs) are stable short sequence (18–22 nucleotides) regulators that
exert post-transcriptional control over gene expression [22,23]. Hanniford et al demonstrated that
a 4-miR signature is sufficient to discriminate primary melanoma tumors that will metastasize to
the brain from those that will not [24]. Also, specific cfmiRs are found in both serum and plasma
of cutaneous melanoma patients as our group and others have demonstrated [23,25–36]. Several
cfmiRs have been proposed as single biomarkers, or in combination to be used for diagnostic and
prognostic assessment of cutaneous melanoma patients [23,37]. Nonetheless, there are concerns that
these cfmiRs are non-cancer related and are associated with normal physiological functions and benign
diseases [23,38].
The major issues in the application of cfmiR assays are specificity, reproducibility, and accuracy.
The main technical concerns of miR assays are: (1) Inconsistencies in study design where the cfmiR
signatures have not been validated in matched tissue samples; (2) fluid sampling volume and
efficient extraction of these small cfmiRs; (3) reproducibility and robustness; and (4) detection of
low level cfmiRs [23,39,40]. To avoid these issues of cfmiR detection, we used a targeted probe,
next generation sequencing (NGS)-based platform (HTG EdgeSeq miRNA Whole Transcriptome Assay
(WTA), HTG Edge System software Host version 5.3.772.5028 and HTG REVEAL software version
2.0.1, HTG Molecular Diagnostic, Inc. Tucson, AZ, USA). HTG miRNA WTA profiles the expression of
2083 miRs, requires minimal sample input (<50 µL), has low processing cost, yields high reproducibility,
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and offers robustness and high accuracy [24]. This platform is based on an extraction-free direct assay
that significantly increases the efficiency of capturing low level miRs; therefore reducing data variability
introduced by nucleic acid isolation techniques, which is a major problem in cfNA blood assay
reproducibility [24,41,42]. More importantly, miRs can be assessed from limited specimen sources.
This study revealed a cfmiR signature found in the plasma of MBM patients, verified in a second
MBM cohort, and corroborated in MBM tissues. We demonstrated that the cfmiR signature detected
in the MBM patients overlap with the cfmiR found in pre-treatment plasma samples from metastatic
melanoma patients receiving CII. CfmiR detection in urine offers a non-invasive body fluid assay that
is more logistically practical for patient compliance. Therefore, we have developed a cfmiR assay
for evaluating urine to complement the plasma cfmiR assessment of CII-treated melanoma patients.
Specific cfmiRs that were upregulated in the plasma were consistently detected in the paired urine
samples of CII-treated melanoma patients.
2. Results
2.1. CfmiRs That Differentiate Plasma from Serum in Normal Healthy Donors
There are various studies on identifying cfmiRs in cancer patients. However, there are limited
analyses published for cfmiR profiling of large cohorts of plasma and serum samples taken from normal
healthy donors [43]. Initially, we assessed and compared normal donors’ plasma and serum using
the HTG miRNA WTA. To determine the reproducibility of the HTG miRNA WTA, normal donors’
plasma (Plasma 1, P1, n = 48) and serum (Serum 1, S1, n = 48) samples were randomly distributed in
a 96-well HTG miRNA WTA. Then, serum (Serum 2, S2, n = 48) and plasma (Plasma 2, P2, n = 48)
samples were obtained from the same healthy donors respectively, and analyzed using HTG miRNA
WTA (Figure 1A). Using the parsed raw read counts, we performed DESeq2 data normalization using
HTG REVEAL software version 2.0.1 and compared S1 to S2. Normal donors’ serum samples S1
and S2 showed similar counts distributions and a correlation value of 0.99 (Figure 1B,C). Similar
comparison and results were observed for plasma samples (P1 and P2, Figure 1B,C). Also, both normal
donors’ serum and plasma samples showed high correlation of the cfmiRs expression (Figure 1C).
To identify differentially expressed (DE) cfmiRs, normal donors’ plasma and serum samples were
compared using HTG REVEAL software version 2.0.1. After data normalization and multiple testing
corrections (false discovery rate (FDR) p < 0.05), only cfmiRs with a fold-change (FC) of >1.2 or <1.2
and count values of >100 after normalization were included in further analysis. The normal donors’
serum (S1 + S2) and plasma (P1 + P2) samples were pooled and evaluated for differences in cfmiR
expression. Overall, the cfmiR profiles were similar for serum and plasma samples, respectively
(Figure 1D and Table 1A,B). Only two cfmiRs showed significant changes in the same serum samples
analyzed in duplicates (Table 1); while no significant changes were observed for plasma samples
analyzed in duplicates. Then, we compared plasma and serum samples. There were 324 DE cfmiRs
in plasma compared to serum samples of which 178 were upregulated and 146 were downregulated
(Figure 1E,F). Additionally, plasma and serum samples were compared for cfmiRs associated with
gender. Plasma samples from males showed 78 DE cfmiRs compared to females, where the majority
(89.7% of the total DE cfmiRs) were upregulated in males versus females (Figure 1G). A similar analysis
was performed for the comparison in serum samples of both genders. A total of 181 cfmiRs were DE in
both genders. While 61 were downregulated, 120 were upregulated in males compared to females
(Figure 1H). When considering the top 10 most variable cfmiRs found in plasma, all 10 cfmiRs were
upregulated (Table 2A). Similar results were observed when considering the top 10 most DE cfmiRs
found in serum, where 9 cfmiRs were upregulated (Table 2B). Finally, we examined for common cfmiRs
consistently changing in plasma and serum samples when comparing males versus females. A total
of 53 cfmiRs were consistently changing in serum and plasma (Table 3). Of the 53 cfmiRs commonly
DE in both comparison, 52 were consistently upregulated in males versus females in both serum and
plasma samples (Figure 1I). In summary, the results showed that there were significant differences in
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plasma and serum cfmiR profiles. There were no significant differences in the cfmiRs profiles analyzed
in plasma samples that were run in duplicates demonstrating the robustness and reproducibility of
the HTG miRNA WTA. Fewer cfmiRs showed significant differences in gender analysis in plasma
compared to serum samples. Subsequent studies on metastatic melanoma patients were performed on
plasma because cfmiR detection in serum can be problematic due to clotting event factors that promote
the release of miRs from leukocytes and platelets. Also, there is a preferential use of plasma in cfNA
clinical assays.
Figure 1. Comparison of serum and plasma samples from normal healthy donors. (A) Schematic
representation of the samples analyzed throughout the study. (B) Cell-free microRNAs (cfmiRs)
normalized counts distribution in serum (S1-S2) and plasma (P1-P2) samples for the first (S1 and P1)
and second sequencing assays (S2 and P2) respectively. (C) Correlation matrix of cfmiRs analyzed
in serum (S1-S2) and plasma (P1-P2) samples for the first (S1 and P1) and second sequencing assays
(S2 and P2) respectively. (D) Heatmap showing the normalized counts of cfmiRs observed in plasma
(P1-P2) and serum (S1-S2) respectively. (E) Heatmap showing the cfmiRs significantly changing in
plasma compared to serum samples. (F) Differentially expressed (DE) cfmiRs in plasma versus serum
samples. (G,H) DE cfmiRs in males versus females observed in plasma (G) and serum (H) samples,
respectively. (I) Commonly DE cfmiRs in males versus females in serum and plasma samples.
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Table 1. DE cfmiRs in the plasma (P1 vs. P2) and serum (S1 vs. S2) samples of normal donors.
(A) Top 10 DE cfmiRs expressed in duplicated plasma samples P1 and P2
Probe Mean NormalizedExpression P1
Mean Normalized
Expression P2 FC P1 vs. P2 p-Value
Adjusted
p-Value
miR-6873-3p 99 133 1.21 0.030 0.999
miR-92b-3p 269 369 1.17 0.081 0.999
miR-1273e 350 454 1.16 0.09 0.999
miR-4274 120 109 −1.09 0.138 0.999
miR-1909-5p 144 163 1.11 0.142 0.999
miR-584-5p 103 141 1.14 0.147 0.999
miR-3157-5p 101 115 1.1 0.179 0.999
miR-6852-3p 95 115 1.12 0.185 0.999
miR-572 171 192 1.1 0.187 0.999
miR-1287-5p 371 430 1.11 0.190 0.999
(B) Top 10 DE cfmiRs expressed in duplicated serum samples S1 and S2
Probe Mean NormalizedExpression S1
Mean Normalized
Expression S2 FC S1 vs. S2 p-Value
Adjusted
p-Value
miR-6819-5p 149 103 1.36 0.0001 0.027
miR-670-3p 189 123 1.39 0.0001 0.030
miR-1303 181 118 1.37 0.000 0.064
miR-1273e 2776 2058 1.26 0.009 0.418
miR-193a-5p 117 89 1.24 0.012 0.478
miR-1290 229 160 1.26 0.017 0.555
miR-1299 527 381 1.25 0.023 0.562
miR-4769-3p 120 102 1.15 0.027 0.588
miR-6852-5p 106 121 −1.13 0.028 0.588
miR-3674 473 357 1.21 0.048 0.703
DE = differentially expressed. CfmiRs = cell-free microRNAs. FC = fold-change. P1 = plasma 1. P2 = plasma 2.
S1 = serum 1. S2 = serum 2. Highlighted in gray are the cfmiRs that were DE in serum samples.
Table 2. The top 10 DE cfmiRs in male (M) versus female (F) in normal donors’ plasma (A) and serum
(B) samples.
(A) Plasma (B) Serum
Probe FC M vs. F Adjusted P-value Probe FC M vs. F Adjusted p-Value
miR-451a 2.29 2.94 × 10−5 miR-143-5p 1.34 1.50 × 10−3
miR-150-5p 1.84 1.10 × 10−3 miR-3943 1.45 2.20 × 10−3
miR-6796-3p 1.45 1.90 × 10−3 miR-8071 1.45 2.80 × 10−3
miR-4726-3p 1.37 2.00 × 10−3 miR-4746-5p 1.38 3.30 × 10−3
miR-3940-5p 1.59 2.00 × 10−3 miR-217 1.38 3.30 × 10−3
miR-3155b 1.42 2.10 × 10−3 miR-4758-5p −1.33 4.40 × 10−3
miR-6798-5p 1.61 2.10 × 10−3 miR-6787-5p 1.38 4.40 × 10−3
miR-486-5p 1.70 2.10 × 10−3 miR-34b-3p 1.34 5.20 × 10−3
miR-3912-5p 1.39 2.50 × 10−3 miR-4522 1.42 5.20 × 10−3
miR-6789-3p 1.30 2.70 × 10−3 miR-193a-3p 1.43 5.20 × 10−3
DE = differentially expressed. CfmiRs = cell-free microRNAs. M =male. F = Female. FC = fold-change.
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Table 3. CfmiRs that are commonly DE in male (M) versus female (F) in both serum and plasma of
normal donors’ samples.
Probe FC Plasma M vs. F Adjusted p-Value FC Serum M vs. F Adjusted p-Value
miR-451a 2.29 2.94 × 10−5 1.41 0.047
miR-150-5p 1.84 1.10 × 10−3 1.44 0.023
miR-8071 1.64 3.80 × 10−3 1.45 0.003
miR-363-3p 1.58 1.16 × 10−2 1.35 0.047
miR-6852-3p 1.56 4.60 × 10−3 1.47 0.007
miR-6870-3p 1.52 8.70 × 10−3 1.31 0.035
miR-92b-3p 1.49 3.57 × 10−2 1.39 0.0387
miR-764 1.48 4.70 × 10−3 1.26 0.044
miR-339-3p 1.48 1.75 × 10−2 1.37 0.025
miR-6825-3p 1.48 1.05 × 10−2 1.43 0.015
miR-6085 1.47 1.17 × 10−2 1.38 0.015
miR-6796-3p 1.45 1.90 × 10−3 1.24 0.046
miR-3155b 1.42 2.10 × 10−3 1.28 0.015
miR-6742-5p 1.42 7.00 × 10−3 1.29 0.018
miR-4309 1.42 5.10 × 10−3 1.29 0.014
miR-1233-3p 1.42 1.03 × 10−2 1.36 0.015
miR-4793-5p 1.42 3.20 × 10−3 1.37 0.009
miR-497-3p 1.41 7.00 × 10−3 1.32 0.014
miR-6069 1.40 7.00 × 10−3 1.3 0.016
miR-640 1.40 8.60 × 10−3 1.33 0.012
miR-5694 1.39 9.80 × 10−3 1.24 0.039
miR-193b-3p 1.39 1.99 × 10−2 1.28 0.011
miR-3912-5p 1.39 2.50 × 10−3 1.31 0.011
miR-4655-3p 1.38 4.40 × 10−3 1.21 0.039
miR-4726-3p 1.37 2.00 × 10−3 1.29 0.010
miR-6715b-3p 1.37 5.10 × 10−3 1.31 0.009
miR-3912-3p 1.37 7.50 × 10−3 1.32 0.011
miR-3124-3p 1.36 6.10 × 10−3 1.26 0.015
miR-33b-5p 1.36 1.66 × 10−2 1.29 0.020
miR-671-5p 1.36 1.63 × 10−2 1.31 0.039
miR-5587-3p 1.35 1.16 × 10−2 1.26 0.027
miR-541-3p 1.35 7.90 × 10−3 1.27 0.036
let-7g-3p 1.35 7.00 × 10−3 1.3 0.011
miR-4291 1.35 1.75 × 10−2 1.32 0.014
miR-2115-5p 1.33 5.40 × 10−3 1.23 0.039
miR-1307-5p 1.33 3.90 × 10−2 1.33 0.024
miR-3157-5p 1.33 1.15 × 10−2 1.36 0.009
miR-217 1.33 1.40 × 10−2 1.38 0.003
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Table 3. Cont.
Probe FC Plasma M vs. F Adjusted p-Value FC Serum M vs. F Adjusted p-Value
miR-937-3p 1.32 6.50 × 10−3 1.2 0.040
miR-187-5p 1.32 1.16 × 10−2 1.3 0.010
miR-4690-5p 1.31 2.70 × 10−2 1.25 0.013
miR-187-3p 1.31 1.50 × 10−2 1.33 0.01
miR-3907 1.30 2.90 × 10−3 1.22 0.03
miR-6789-3p 1.30 2.70 × 10−3 1.27 0.01
miR-2115-3p 1.30 7.70 × 10−3 1.28 0.011
miR-4279 1.30 2.73 × 10−2 1.29 0.014
miR-3714 1.30 1.30 × 10−2 1.34 0.005
miR-1909-5p 1.29 1.45 × 10−2 1.26 0.022
miR-4537 1.29 7.00 × 10−3 1.27 0.011
miR-3689d 1.27 1.65 × 10−2 1.31 0.007
miR-935 1.22 3.85 × 10−2 1.23 0.015
miR-4746-5p 1.21 4.53 × 10−2 1.38 0.003
miR-1273h-5p −1.51 3.56 × 10−2 −1.33 0.034
CfmiRs = cell-free microRNAs. DE = differentially expressed. M = male. F = Female. FC = fold-change.
2.2. A CfmiR Signature That Identifies MBM Patients from Normal Healthy Donors’ Plasma
MBMs are one of the most devastating and difficult metastases to treat. Thus, earlier MBM
detection, identification of progressive disease, and treatment response are critical to improve overall
outcomes. All blood cfmiR analysis from this point on will be referring to plasma samples. Pre-operative
samples from MBM patients (MBM-01, n = 36, Table 4) were assessed to determine cfmiR signatures
that could identify the MBM from normal donors’ samples (P1, n = 48). For MBM and normal
donors’ comparison, the same exclusion criteria was used to exclude cfmiRs with low detectability
and that were not significantly changing (FDR p < 0.05, FC > 1.2, or <1.2 and count values >100 after
normalization). The results showed that 164 cfmiRs were significantly DE in MBM patients’ compared
to normal donors’ samples, of which 79.9% (131 of 164) were upregulated, and 20.1% (33 of 164) were
downregulated (Figure 2A). In Figure 2B, the top 5 DE cfmiRs with the highest detection level in MBM
patients compared to normal donors’ samples are shown. Also, the top 10 most DE cfmiRs are shown
(Figure 2C).
Table 4. Clinical demographics of melanoma brain metastasis (MBM) patients analyzed.
MBM-01 MBM-02
Variables n (%) n (%)
Age at diagnosis, year, mean (SD) 49 (26) 55 (14)
Age at MBM diagnosis, year, mean (SD) 52 (28) 60 (13)
Gender
Male 24 (66.7) 14 (58.3)
Female 12 (33.3) 10 (41.7)
MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma brain metastasis second cohort.
SD = standard desviation.
To verify the cfmiR signature obtained in the first cohort of MBM patients, we assessed a second
cohort of MBM patients (MBM-02, n = 24, Table 4). Pre-operative plasma samples from the second
cohort of MBM (n = 24) patients were assessed and compared to normal donors’ samples (P1, n = 48).
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We observed 166 DE cfmiRs in MBM patients compared to normal donors’ samples (FDR p < 0.05,
FC > 1.2, or <1.2 and count values >100 after normalization). Of the 166 cfmiRs, 68 were downregulated
and 98 were upregulated (Figure 2D). Surprisingly, 74 were consistently changing in both MBM cohorts.
While 20 were consistently downregulated, 54 were upregulated (Figure 2E).
Figure 2. Differentially expressed (DE) cell-free microRNAs (cfmiRs) in serum versus plasma from
normal healthy donors’ samples. (A) Schematic of the cfmiRs DE, either up- or down-regulated in the
plasma of melanoma brain metastasis first cohort (MBM-01) patients compared to the normal donors’
samples. (B) Boxplots showing the top 5 DE cfmiRs with the highest detection levels in MBM-01
patients compared to normal donors’ samples (*** p < 0.001). (C) Boxplots showing the top 10 most DE
cfmiR in MBM-01 patients compared to normal donors’ samples (*** p < 0.001). (D) Schematic of the
cfmiRs DE, either up- or down-regulated in the plasma of melanoma brain metastasis second cohort
(MBM-02) patients compared to the normal donors’ samples. (E) Comparison of the DE cfmiRs and
changing inconsistently or consistently in MBM-01 and MBM-02 patients’ cohorts.
To corroborate the origin of the MBM cfmiR signature, we analyzed a cohort of MBM tissues
(n = 24) and compared the 74 cfmiR profiles commonly changing in the two cohorts of MBM patients’
compared to normal donors’ samples. We found 16 (21.6%) cfmiRs changing in MBM plasma that
7 were not present in MBM tissues (Table 5) and 58 (78.4%) DE cfmiRs in MBM plasma that were
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consistently expressed in the MBM tissues (Figure 3A). This 58 cfmiR signature was verified to
differentiate MBM patients from normal donors’ samples using principal component analysis (PCA,
Figure 3B). The first five components of the PCA showed 82.5% and 89.1% mean cumulative variance
in MBM-01 and MBM-02 respectively (Table 6). To determine the association among the cfmiRs
identified, the 58 cfmiRs were clustered based on their correlation values. Three main clusters
(cluster 1, 2, and 3) were observed in the correlation matrix (Figure 3C, Table 7A–C). Moreover,
two clusters showed that members of the same family clustered together (i.e. cluster 1: miR-320b and
miR-320d, miR-181b-5p and miR-181a-5p, miR-99b-5p and miR-99a-5p; cluster 3: miR-1273a, miR-1273c,
miR-1273e, and miR-1273g-5p). To summarize, we identified a 74 cfmiR signature differentiating MBM
patients’ from normal donors’ samples that were consistently present in the MBM tissues analyzed.
These results also validated the hypothesis that there is consistency between the cfmiRs observed in
the MBM patients’ plasma and tumors.
Table 5. CfmiRs that are commonly DE in MBM-01 and MBM-02 plasma samples compared to normal
donors’ samples not present in the MBM tissues.
Probe FC MBM-01 vs. Normal Adjusted p-Value FC MBM-02 vs. Normal Adjusted p-Value
miR-6741-3p 6.46 7.65 × 10−37 3.02 6.24 × 10−15
miR-6852-3p 5.34 2.41 × 10−22 4.9 7.63 × 10−26
miR-4689 4.14 1.21 × 10−27 6.84 4.66 × 10−41
miR-3943 3.56 6.57 × 10−21 3.01 2.44 × 10−21
miR-541-3p 3.34 8.31 × 10−18 1.56 7.64 × 10−4
miR-3157-5p 3.12 2.07 × 10−17 3.27 1.08 × 10−24
miR-4784 2.44 1.27 × 10−13 1.73 3.33 × 10−7
miR-4279 2.36 2.28 × 10−9 1.79 5.84 × 10−6
miR-4664-3p 2.17 1.96 × 10−10 4.31 7.29 × 10−24
miR-4291 1.93 1.26 × 10−5 2.63 2.68 × 10−19
miR-3912-5p 1.88 7.34 × 10−7 1.71 1.14 × 10−7
miR-5694 1.82 2.47 × 10−4 1.46 6.00 × 10−3
miR-3912-3p 1.79 1.35 × 10−5 1.57 4.39 × 10−5
miR-670-3p 1.78 3.53 × 10−5 2.66 3.32 × 10−22
miR-4665-5p 1.68 2.79 × 10−4 5.89 2.77 × 10−23
miR-3937 1.67 1.10 × 10−3 2.98 3.76 × 10−8
DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort.
MBM-02 = melanoma brain metastasis second cohort. MBM = Melanoma brain metastasis. FC = fold-change.
Table 6. Statistics of PCA analysis of Figure 3B.















PC1 4.906 0.310 0.310 7.011 0.457 0.457
PC2 4.383 0.248 0.558 4.782 0.213 0.670
PC3 3.438 0.152 0.711 3.676 0.126 0.795
PC4 2.452 0.078 0.788 2.458 0.056 0.851
PC5 1.686 0.037 0.825 2.061 0.039 0.891
PCA = principal components analysis. MBM-01 = melanoma brain metastasis first cohort. MBM-02 = melanoma
brain metastasis second cohort. PC = principal components.
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Figure 3. A Cell-free microRNA (cfmiR) signature in the plasma that differentiates melanoma brain
metastasis (MBM) patients’ from normal donors’ samples. (A) Scheme of the differentially expressed
(DE) cfmiRs in MBM patients compared to normal donors’ samples that were detected in MBM tissue
samples. (B) Principal component analysis (PCA) analysis of the 58 DE cfmiRs in MBM-01 (left) or
MBM-02 (right) patients versus normal donors’ samples that were also present in the MBM tissues.
(C) Clustering of the 58 cfmiRs that differentiate MBM patients from normal donors’ samples. Three
clusters were identified: cluster 1 (pink), cluster 2 (green), and cluster 3 (blue).
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Table 7. DE cfmiRs in MBM-01 and MBM-02 vs. normal donors’ plasma that were also detected in












miR-100-5p 150 79 98
miR-125b-5p 235 134 126
miR-181a-5p 1499 842 969
miR-181b-5p 191 113 119
miR-320b 4407 2417 3146
miR-320d 2445 1617 1685
miR-338-3p 224 130 112
miR-342-3p 413 227 285
miR-378a-3p 210 139 126
miR-378f 136 91 82
miR-378g 181 130 118
miR-378i 217 152 133
miR-4461 3221 1837 1113
miR-6126 108,094 78,636 79,367
miR-99a-5p 381 146 195












miR-1228-3p 92 127 171
miR-1233-3p 234 997 1573
miR-1307-3p 1067 1554 2763
miR-1307-5p 787 2465 1792
miR-143-5p 90 114 239
miR-187-3p 135 185 282
miR-339-3p 289 4295 1437
miR-4667-5p 88 160 237
miR-671-5p 162 1274 539
miR-6789-3p 100 147 178
miR-6796-3p 283 681 1513
miR-6825-3p 173 438 586
miR-6892-3p 409 514 808













miR-1207-5p 478 759 1354
miR-1225-3p 188 462 609
miR-1273a 109 208 308
miR-1273c 171 243 357
miR-1273e 428 1248 1914
miR-1273g-5p 96 129 176
miR-1299 109 342 318
miR-3135a 81 126 216
miR-3674 88 178 224
miR-548d-5p 144 248 337
miR-5585-3p 1372 2369 3112
miR-574-5p 1632 4042 7203
miR-6775-5p 143 263 279
DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort.
MBM-02 = melanoma brain metastasis second cohort. MBM = Melanoma brain metastasis.
2.3. CfmiRs That Differentiate MBM from Other Brain Tumors
We assessed plasma samples from breast cancer brain metastasis (BCBM) and lung cancer brain
metastasis (LuBM), and compared them to MBM patients for identification of distinct cfmiR signatures.
BCBM (n = 7) and LuBM (n = 6) patients samples cfmiR profiles were analyzed and compared to those
obtained from the MBM plasma samples (MBM-01, n = 36). For this analysis the same exclusion criteria
were used (FDR p < 0.05, FC > 1.2 or <1.2, and count values >100 after normalization). MBM patients
revealed 218 DE cfmiRs compared to BCBM patients (Figure 4A); 35 cfmiR were upregulated and 183
were downregulated in MBM compared to BCBM patients. Similar comparisons were performed in
MBM versus LuBM patients. MBM showed that 23 cfmiRs were DE; of these 15 were upregulated
and 8 were downregulated (Figure 4B). In summary, 218 and 23 DE cfmiRs were found in the MBM
patients when compared to the BCBM and LuBM patients, respectively.
Next, we analyzed for cfmiRs in a cohort of glioblastoma (GBM, n = 36) plasma samples. CfmiRs
from the first cohort of MBM patients were compared to the cfmiR profiles obtained from the GBM
patients. We found that 84 cfmiRs were DE in MBM patients versus GBM patients of which 58 were
upregulated and 26 were downregulated (Figure 4C). Through integrated data analysis of the cfmiRs
commonly identified as DE between normal donors and MBM (74 DE cfmiRs), BCBM and MBM
(218 DE cfmiRs), LuBM and MBM (23 DE cfmiRs), and GBM and MBM (84 DE cfmiRs) plasma
samples, only 6 cfmiRs remained commonly DE and detected in all of the comparisons (Figure 4D).
These 6 cfmiRs could be used as a potential diagnostic tool to discriminate MBM from LuBM, BCBM,
and GBM patients. Then, we searched for cfmiRs that exclusively distinguished MBM patients from
normal donors’ samples that were not present in LuBM, BCBM, and GBM patients. The initial 74 cfmiRs,
identified in both MBM cohorts, were compared with those DE cfmiRs found in the comparisons of all
the respective brain tumor types. An exclusive signature of 29 cfmiRs differentiated MBM from the
other brain tumors and normal donors (Figure 4E and Table 8). This 6 cfmiR signature combined with
a 29 specific cfmiR signature found in MBM plasma samples may potentially allow for the assessment
of melanoma patients developing MBM. More samples are needed to be analyzed in future studies to
validate our conclusions.
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Figure 4. Cell-free microRNAs (cfmiRs) that differentiate melanoma brain metastasis (MBM) patients
from extracranial cancer brain metastasis and glioblastoma (GBM) patients. (A,B) Schematic summary
of the cfmiRs identified in MBM vs. breast cancer brain metastasis (BCBM) (A), MBM vs. lung
cancer brain metastasis (LuBM), (B), MBM vs. GBM (C). (D) A 6 cfmiR signature was identified after
comparisons of MBM vs. normal donors to MBM vs. BCBM, MBM vs. LuBM, and MBM vs. GBM
plasma samples as summarized in the Table. (E) A 29 cfmiR signature was able to distinguish MBM
from other primary and metastatic brain tumors. For details on the cfmiRs identified refer to Table 8.
Table 8. 29 DE cfmiRs in MBM patients’ plasma.
Probe FC MBM-01 vs. Normal Adjusted p-Value FC MBM-02 vs. Normal Adjusted p-Value
miR-3937 1.67 1.10 × 10−3 2.98 2.09 × 10−9
miR-1299 2.25 1.07 × 10−4 2.95 2.54 × 10−10
miR-1273e 3.36 2.30 × 10−10 2.79 1.13 × 10−12
miR-670-3p 1.78 3.53 × 10−5 2.66 2.96 × 10−24
miR-1225-3p 2.55 2.52 × 10−10 2.42 3.85 × 10−16
miR-574-5p 3.27 2.52 × 10−9 2.36 3.05 × 10−7
miR-6780b-5p 1.90 1.20 × 10−3 2.01 6.58 × 10−7
miR-3674 1.96 5.90 × 10−3 1.95 3.72 × 10−4
miR-7111-5p 1.69 6.50 × 10−3 1.89 1.30 × 10−6
miR-1273a 2.22 7.15 × 10−6 1.85 1.06 × 10−4
miR-6877-5p 1.53 2.92 × 10−2 1.84 2.85 × 10−5
miR-6775-5p 1.57 3.50 × 10−3 1.81 2.34 × 10−6
miR-4279 2.36 2.28 × 10−9 1.79 7.18 × 10−7
miR-5585-3p 1.77 5.80 × 10−3 1.69 3.48 × 10−4
miR-548d-5p 1.81 1.29 × 10−2 1.66 7.80 × 10−3
miR-7114-3p 1.88 1.70 × 10−6 1.65 2.27 × 10−8
miR-1207-5p 2.23 1.83 × 10−7 1.58 1.71 × 10−5
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Table 8. Cont.
Probe FC MBM-01 vs. Normal Adjusted p-Value FC MBM-02 vs. Normal Adjusted p-Value
miR-3135a 2.12 1.08 × 10−5 1.55 6.26 × 10−4
miR-6789-3p 1.44 2.20 × 10−3 1.46 1.23 × 10−5
miR-1273c 1.67 6.20 × 10−3 1.41 1.63 × 10−2
miR-1228-3p 1.50 2.80 × 10−3 1.38 5.43 × 10−4
miR-1273g-5p 1.48 2.29 × 10−2 1.35 1.77 × 10−2
miR-143-5p 2.12 5.05 × 10−11 1.26 4.60 × 10−3
miR-6795-3p −1.31 1.43 × 10−2 −1.26 7.06 × 10−4
miR-6126 –1.63 2.06 × 10−2 −1.36 1.90 × 10−2
miR-920 –1.64 1.51 × 10−8 −1.42 1.18 × 10−4
miR-378f –2.02 4.64 × 10−10 −1.5 1.53 × 10−5
miR-3663-5p –2.33 4.44 × 10−12 −1.7 2.23 × 10−5
miR-3184-3p −1430.32 1.02 × 10−105 −2.07 2.78 × 10−11
DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort.
MBM-02 = melanoma brain metastasis second cohort. MBM = Melanoma brain metastasis. FC = fold-change.
2.4. CfmiR in Patients Treated with Checkpoint Inhibitor Immunotherapy
CII has become the standard of care for metastatic melanoma patients in the last several years
and has improved survival outcomes [8]. However, monitoring patients to determine their treatment
response remains a major problem. To identify specific cfmiR signatures, in plasma and urine samples
from pre- and post-CII-treated melanoma patients (Table 9) were assessed using the HTG miRNA WTA.
Plasma samples obtained from both pre- and post-treatment groups were compared to normal donors’
samples. We identified 219 and 228 cfmiRs as DE in pre- and post-treatment CII patients compared to
normal donors’ samples, respectively (Figure 5A). A total of 196 cfmiRs were consistently changing in
pre- and post-treatment samples. 18 cfmiRs showed a decrease in expression levels, while 178 cfmiRs
showed an increase when compared to the normal donors’ samples (Figure 5B). It should be noted that
89.5% of cfmiRs were consistently up or downregulated in the pre- and post-treatment paired samples,
respectively. Only 10.5% (22 of 219) of cfmiRs that were detected in pre-treatment samples were not
significantly changing in post-treatment samples (data not shown). Also, 8 DE cfmiRs identified in pre-
and post-treatment samples were also detected in MBMs but not in other brain cancer metastasis or
primary brain tumors (Table 10).
Table 9. Clinical pathological information for metastatic melanoma patients receiving CII analyzed for
cfmiRs in plasma and urine samples.
Plasma (n = 20) Urine (n = 14) Paired Plasma and Urine (n = 11)
Variables n (%) n (%) n (%)
Age, year, mean (SD) 61.8 (21.1) 59.7 (24.9) 55 (13)
Gender
Male 13 (66.7) 9 (64.3) 6 (54.5)
Female 7 (33.3) 5 (35.4) 5 (45.5)
AJCC 8th stages
III b/c 3 (15) 4 (28.6) 2 (18.2)
IV b/c/d 17 (85) 10 (71.4) 9 (81.8)
BRAF mutations
Positive 12 (60) 9 (64.3) 7 (63.6)
Negative 8 (40) 5 (35.7) 4 (36.4)
Number of metastasis
1 17 (85) 13 (92.9) 10 (85)
2–3 3 (15) 1 (7.1) 1 (15)
CII = checkpoint immune inhibitor. Cell-free microRNAs = cfmiRs. AJCC 8th stages at the start of the specific CII.
SD = standard deviation.
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Figure 5. Cell- free miRNA (cfmiR) signatures in urine and plasma of melanoma patients receiving
checkpoint immune inhibitor (CII). (A) Scheme of the differentially expressed (DE) cell-free microRNAs
(cfmiRs) in pre- (left) and post-treatment (right) plasma samples compared to normal donors’ plasma
samples. (B) CfmiRs detected in plasma samples from pre- and post-treatment melanoma patients
receiving CII that were inconsistently or consistently changing. (C) Comparison of the 35 cfmiRs
melanoma brain metastasis (MBM) signature with the cfmiRs detected in pre-treatment CII plasma
samples. (D) CfmiRs identified in normal donors’ urine, plasma, or found in both. (E) DE cfmiRs
detected in urine samples from pre- (left) and post-treatment (right) melanoma patients receiving
CII. (F) CfmiRs detected in urine samples from pre- and post-treatment melanoma patients receiving
CII that were inconsistently or consistently changing. (G) DE cfmiRs that were inconsistently and
consistently changing in pre-treatment plasma (left) and urine (right) from melanoma patients receiving
CII compared to normal plasma and urine respectively. (H) Receiver operating characteristic (ROC)
curves for the 35 cfmiRs DE in MBM and the associated areas under curves (AUCs).
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Table 10. CfmiRs that were DE expressed in MBM-01 and MBM-02 cohorts that were also detected in
pre- and post-treatment samples of metastatic melanoma patients receiving CII.













miR-3184-3p −2.07 −1430.32 NDE NDE NDE −2669.64 −3258.79
miR-143-5p 1.26 2.12 NDE NDE NDE 1.81 2.96
miR-6789-3p 1.46 1.44 NDE NDE NDE 1.6 2.94
miR-1207-5p 1.58 2.23 NDE NDE NDE 1.54 1.62
miR-7114-3p 1.65 1.88 NDE NDE NDE 3.07 5
miR-4279 1.79 2.36 NDE NDE NDE 2.87 4.74
miR-1225-3p 2.42 2.55 NDE NDE NDE 1.4 2.01
miR-670-3p 2.66 1.78 NDE NDE NDE 1.45 1.75
DE = differentially expressed. CfmiRs = cell-free microRNAs. MBM-01 = melanoma brain metastasis first cohort.
MBM-02 = melanoma brain metastasis second cohort. CII = checkpoint immune inhibitor. MBM = Melanoma
brain metastasis. FC = fold-change. LuBM = lung brain metastasis. BCBM = breast cancer brain metastasis.
GBM = glioblastoma. NDE = not detected as DE in the comparison.
It still remains unknown whether these cfmiRs relate to the clinical course of the disease and if
they can be used to monitor a patients’ response to CII-treatment. CfmiRs may be applied to detect
immune-related adverse events (IRAE) pre-symptomatically, however, further studies are needed to
test this hypothesis.
Consistently, 22.9% (8 of 35) of the DE cfmiRs identified in the two MBM cohorts were also found to
be enhanced in the pre-treatment samples of metastatic CII patients (Figure 5C). To summarize, specific
cfmiRs are detectable in pre- and post-treatment samples of CII patients. Also, 8 of the 35 cfmiRs MBM
signature overlapped with pre-treatment samples of melanoma patients receiving CII.
2.5. CfmiR in Urine
CfmiRs in the blood are filtered by the kidney and excreted from the body in the urine. Since the
cfmiRs found in the urine are generally diluted, we developed a novel isolation assay to purify and
concentrate the cfNA from 15 mL of urine (see Materials and Methods). cfNAs isolated from urine were
analyzed using HTG miRNA WTA. Initially, we assessed urine cfmiRs from normal healthy donors
(n = 8) in duplicates demonstrating reproducibility. The analysis demonstrated that 251 cfmiRs were
detected in normal donors’ urine samples using the same cutoff conditions as established for plasma
analysis (Figure 5D). 55% (138 of 251) of the cfmiRs detected in normal donors’ urine samples were
also present in normal donors’ plasma samples (Figure 5D). Of note, the urine and plasma samples
were not isolated from the same patients in these studies.
On establishment of the urine cfmiR assay, we then analyzed the urine collected from 14 metastatic
melanoma patients (Table 9). Normal donors’ urine samples were then compared with pre- and
post-treatment urine samples collected from melanoma patients receiving CII. In this analysis 96 cfmiRs
were DE in pre-treatment compared to normal donors’ urine samples; while 93 cfmiRs were observed
in post-treatment urine samples when compared to normal donors’ urine samples (Figure 5E). In both
pre- and post-treatment, 77 cfmiRs were consistently DE (Figure 5F).
In order to determine cfmiRs consistently detected in plasma and urine, 11 metastatic melanoma
patients with paired pre-treatment plasma and urine samples were compared. Consistently, 7 cfmiRs
were increased in the pre-treatment plasma and urine samples (Figure 5G). Of these 7 cfmiRs, 3 cfmiRs
(miR-6796-3p, miR-7114-3p, and miR-1207-5p) were also observed in the 58 cfmiRs detected in MBM
plasma and tissues samples and in the 35 cfmiR signature proposed. Surprisingly, miR-7114-3p and
miR-1207-5p were also detected in post-treatment plasma (Table 10). Receiver operating characteristic
(ROC) curve for the 35 cfmiR signature detected in MBM. Optimal balance between sensitivity (86.7%)
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and specificity (83.3%) (Area under the ROC curve (AUC) 0.911, 95% CI: 0.855 – 0.966, p < 0.001) at
10 cfmiR as a cutoff value (Figure 5H).
3. Discussion
Recently cfNA assays have shown promising utility as blood cancer biomarkers particularly
when compared to other types of blood cancer biomarkers such as proteins and circulating tumor
cells [1,20,23,39,40,44–48]. Many cfNA cancer assays have been Food and Drug Administration (FDA)
and Clinical Laboratory Improvement Amendments (CLIA) approved for deciding different cancers’
treatment implementation in the USA and Europe. However, there are still limitations and concerns
associated with cfDNA such as the isolation, assay sensitivity, multiple profiling, analytics, and
degradation. All of these factors can affect the final results’ interpretation [14,39,40]. To overcome these
issues, we utilized a modified HTG miRNA WTA to successfully assess cfmiR found in the plasma and
urine samples from cancer patients.
Our results demonstrated the robustness of the HTG miRNA WTA in detecting cfmiRs in both
serum, plasma, and urine samples. The comparison between normal donors’ serum and plasma
demonstrated differences in 324 cfmiRs. There are various explanations for this observation, as other
groups have shown and discussed previously [14,39,40,44,45]. The limitation in serum analysis is
the miRs contamination during blood clotting [39,40]. Differences between serum and plasma could
be linked to the presence of extracellular vesicles containing high levels of miRs in the serum [49].
In general, plasma has become the standard blood fluid analytic source for cfNA assays in cancer patient
analysis. Our results showed a higher reproducibility in plasma compared to serum, and reduced
variability in gender comparisons in plasma.
A 74 cfmiR signature was detected in two MBM patient plasma cohorts when compared to normal
donors’ plasma. Only 58 cfmiRs were consistently detected in MBM tissues. The better explanation for
this discrepancy between cfmiRs in MBM patients’ plasma and tumor tissue may arise from differences
in the cfmiRs released from the tumor microenvironment, absorption from tumor adjacent normal
cells, dilution effect in blood, and filtrations in different organs. Tumor microenvironment contains
cells such as immune cells, supporting stroma cells, and/or activated normal brain tissue cells that may
account for the release of cfmiRs during brain tumor establishment and progression [36,50].
In the cfmiR comparisons of MBM versus other extracranial origin brain cancer metastasis and
GBM, we refined and selected a 6 and 29 cfmiR signature, respectively. The former signature pattern
has a potential screening utility to distinguish MBM from other brain metastasis of common tumors
and GBM. This signature may have utility in screening patients with brain tumors with an unknown
primary tumor. The 29 cfmiR signature in combination with the 6 cfmiR signature may be utilized
to monitor MBM patients post-surgery for early disease progression. However, further validation is
required for the second signature in an independent cohort of BCBM, LuBM, and GBM patients.
The 35 cfmiR signature identified in MBM were also assessed in pre- and post-treatment plasma
samples taken from melanoma patients receiving CII. Interestingly, 8 DE cfmiRs that were exclusively
detected in MBM plasma were also detected in the pre- and post-treatment plasma of patients receiving
CII. Further validation in a larger independent cohort of melanoma patients receiving CII, with serial
blood samples, and Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) evaluation will be
needed in future studies. Successful detection of early progression of CII-treated patients, who have
failed treatment, and/or develop MBM will be an important real-time blood diagnostic tool to assist in
making treatment decisions for patients.
Urine is an alternative non-invasive body fluid source for assessing cfmiRs. There are several
advantages associated with urine-based assays: (1) Non-invasive procedures, (2) can be repetitively
monitored, (3) easier compliance by patients, and (4) larger volumes of fluids can be obtained [11].
The procurement of large volumes of blood from CII patients for clinical tests and research purposes is
not always feasible. This issue is more prevalent in older patients and in patients who have difficulty
having routine blood samples drawn. Conversely, a limitation for cfmiR assessment in urine is the
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detection of representative cfmiRs derived from tumor cells. Usually cfmiR present in the urine
represents those present at high levels in the blood. Many cfmiRs may be filtered out in the kidneys
and eventually destroyed in the urine due to pH and other physiological aspects of urine such as
metabolic contaminants in urine. Other factors known to influence clinical testing of urine biomarker
detection include diurnal fluctuations, time of void collections as related to fluid intake or diuretics,
cancer drug treatment, age, etc. Further technical and logistical developments will improve cfmiRs
detection in urine.
Previous studies have identified cfmiRs in different body fluids and have demonstrated how they
are distributed [51–53]. Ashish et al isolated and sequenced total extracellular RNA from 183 plasma
samples, 204 urine samples, and 46 saliva samples from 55 healthy donors, and found that 84 out of
92 miRNAs detected in urine samples were also detected in plasma samples [51]. Our urine analysis
showed a similar number of cfmiR detected when compared to plasma. In the present study, we showed
that specific cfmiRs identified in the MBM plasma were also detected in the pre- and post-treatment
plasma samples from patients receiving CII, and consistently detected in the paired urine samples.
The urine studies demonstrated the potential utility of the assays to detect cfmiRs in pre- and
post-treatment plasma samples from metastatic melanoma patients that may be associated to CII
patients’ status. Further studies are needed to increase the sample size and to validate our findings.
This study is novel compared to previous studies published in the field of non-urological cancer
detection because of: (1) The detection of signatures instead of single biomarkers, (2) the low volumes of
blood (<50 µL) required for using a direct assay, (3) the assay relies on an NGS-based platform providing
high specificity, (4) the several verification steps that have been included to obtain reproducible cfmiR
signatures, and (5) the development of a urine assay enabling cfmiR assessment from melanoma
patients. Hence, these findings can be translated into a diagnostic assay for cfmiR monitoring of
metastatic melanoma patients.
4. Materials and Methods
4.1. Consent to Participate and Patient Specimen Accrual
This pilot study followed the principles in the Declaration of Helsinki. All human samples and
clinical information for this study were obtained according to the protocol guidelines approved by
the Saint John’s Health Center (SJHC)/John Wayne Cancer Institute (JWCI) Joint Institutional Review
Board (IRB): JWCI Universal Consent (Providence Health System Portland IRB: JWCI-18-0401) and
Western IRB: MORD-RTPCR-0995. Informed consent was obtained from all participants.
4.1.1. Blood and Urine
Blood samples of healthy donors and cancer patients were obtained at SJHC/JWCI. Blood samples
were accrued and processed to obtain serum or plasma. Briefly, all blood samples that were used
for plasma isolation were collected in Streck tubes (Streck, La Vista, NE, USA), processed, aliquoted,
barcoded, and cryopreserved at −80 ◦C as previously described [15]. Blood samples that were used
for serum isolation were collected in BD Vacutainer®Venous Blood Collection Tubes, BD Diagnostics
(VWR, Radnor, PA, USA) and allowed to clot at RT for 1–3 hours, centrifuged, processed as serum,
filtered for cell contamination, and cryopreserved at −80 ◦C as previously described [15]. Aliquots of
serum or plasma were thawed only once and mixed, before being analyzed for miR profiling by HTG
miRNA WTA. Serum (n = 48) and plasma (n = 48) were collected from normal healthy donors ranging in
age from 21–65 years old and were analyzed twice using HTG miRNA WTA. Single pre-operative blood
samples from MBM (n = 36, first cohort), MBM (n = 24, second cohort), GBM (n = 36), BCBM (n = 7),
and LuBM (n = 6) were collected and analyzed using HTG miRNA WTA. Pre- and post-treatment
plasma samples from metastatic cutaneous melanoma CII-treated (n = 20) patients were also collected
and analyzed using HTG miRNA WTA.
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Urine samples from healthy donors (n = 8) and melanoma patients with paired pre- (n = 14)
and post-treatment (n = 14) urine samples were collected and processed for miR NGS detection as
described in Section 4.2.5. Urine samples were collected using a standard sterile 100 mL urine collection
cup (Medtronic, Minneapolis, MN, USA). Each urine cup contained Ethylenediamine tetraacetic acid
(EDTA) 0.05M pH 8.0 (Bioworld, Little Rock, AR, USA). Total DNA/RNA (~139 ng) was extracted
from a 15 mL urine sample using the urine nucleic acid isolation kits and the automated nucleic acid
isolation system (JBS Science, Inc., Doylestown, PA, USA). The isolated nucleic acids in elution buffer
were then aliquoted and cryostored in a −80 ◦C freezer until needed for assays.
Eleven patients’ paired urine and blood samples were collected prospectively from melanoma
patients. CII treatment responses were assessed at every patient follow-up visit at the cancer clinic as
recommended as the standard treatment for the FDA-approved CII drugs (Ipilimumab, Nivolimumab,
and Pembrolizumab) [15]. Briefly, computerized tomography/magnetic resonance imaging was
assessed every three months according to the Response Evaluation Criteria In Solid Tumors 1.1
(RECIST), denoting progressive disease (PD), stable disease (SD), partial response (PR), complete
response (CR), or no evidence of disease (NED). This study was performed in accordance with
the Reporting recommendations for tumour marker (REMARK) guidelines [54,55]. The clinical
demographics of the melanoma patients analyzed are summarized in Tables 4 and 9.
4.1.2. MBM FFPE Tissues
MBM tissues were obtained from elective surgeries performed at SJHC. Formalin-fixed
paraffin-embedded (FFPE) tissues from MBM patients (n = 24) were obtained for HTG miRNA
WTA. FFPE MBM tissue sections were cut into 5 µm sections and the tumor areas were micro-dissected
with sterile scalpels and dissection needles. Hematoxylin and Eosin (H&E) stained slides marked by a
surgical pathologist were used as a guide to determine the area of interest and to avoid including any
normal, non-tumor, or necrotic tissue. The tumor tissue section, as determined by H&E, was measured
for its total surface area. FFPE tissue sections of approximately 10 mm2 were required; multiple slides
were micro-dissected for tissue sections less than 10 mm2. Sections with tumor tissues exceeding a
surface area of 10 mm2 were scraped entirely into their respective tubes. Stained H&E slides were
overlaid with the unstained slides and then used as templates for micro-dissection. Micro-dissected
tissues were processed as described in Section 4.2.3.
4.2. Sample Processing for HTG miRNA WTA
For normal donors’ serum/plasma controls, processing and library preparation were performed
as described in Sections 4.2.1 and 4.2.2. For tissue analysis, the samples were processed as described
in Sections 4.2.3 and 4.2.4. Urine processing and library preparation were performed as described in
Section 4.2.5.
4.2.1. Serum and Plasma Processing for HTG miRNA WTA
Normal donors’ controls and cancer patients’ serum and plasma samples were thawed, mixed, and
analyzed using the HTG miRNA WTA following the manufactures’ recommendations. Serum/plasma
(30 µL) were lysed with HTG Biofluids buffer or Plasma Lysis buffer, respectively with Proteinase K
(HTG Molecular Diagnostics Inc., Tucson, AZ, USA). Lysed samples were incubated on a heat block at
50 ◦C for three hours and each hour the samples were mixed by pipetting. Lysed samples were then
processed on the automated HTG EdgeSeq instrument for probe-capture of 2083 validated human
miRs for 20 hours. After probe-capture, the samples were processed for NGS library preparation.
4.2.2. Serum and Plasma Library Preparation
Probe-captured miR samples were then amplified and indexed via polymerase chain reaction
(PCR) using master mix (10 mM deoxyribonucleotide triphosphate (dNTP) 5×Hemo Klentaq®Reaction
buffer, Hemo Klentaq®DNA polymerase (New England Biolabs Inc., Ipswich, MA, USA), forward,
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and reverse primers (HTG Molecular Diagnostics Inc., Tucson, AZ, USA)). The PCR conditions for the
reactions were: (1) 95 ◦C for 4 min, (2) 95 ◦C for 15 s, (3) 56 ◦C for 45 s, (4) 68 ◦C for 45 s, (5) repeat steps
2–4 for 16 total cycles, (6) 68 ◦C for 10 min, and (7) hold at 4 ◦C. Following PCR, library cleanup was
performed using Ampure® XP beads (Beckman Coulter Inc., Brea, CA, USA). The samples were mixed
and incubated with the beads at room temperature (RT) for 5 min. The bead-bound libraries were then
washed twice with 80% ethanol to remove any leftover PCR reagents and enzymes. After washing, the
samples were dried at RT for 2 min to allow the residual ethanol to evaporate. The libraries were then
eluted off the beads with 10 mM Tris hydrochloride (Tris-HCl), pH 8.0.
4.2.3. MBM Tissue Processing for HTG miRNA WTA
Micro-dissected FFPE tissues were digested in a calculated volume of HTG Lysis buffer equaling
25 µL of Lysis buffer per 10 mm2 of total target tissue. HTG denaturation oil was then overlaid on top
of each FFPE-Lysis buffer sample. Samples were incubated at 95 ◦C for 15 min to denature protein
structures and remove paraffin wax from the FFPE tissue sections. Samples were cooled down for
10 min at RT and an HTG-provided Proteinase K was pipetted into the aqueous (lysis, non-oil) phase
of the samples at a volume 1/20th of the total lysis buffer. The samples were finally incubated at 50 ◦C
for three hours, mixing the aqueous phase by pipetting every hour before loading 25 µL of the sample
lysate onto the HTG EdgeSeq instrument for miR probe-capture.
4.2.4. MBM Tissue Library Preparation
Probe-captured MBM FFPE miR samples were then amplified and indexed via PCR using the
master mix (OneTaq HotStart 2X MasterMix in GC Buffer (New England Biolabs Inc., Ipswich, MA,
USA), with forward and reverse primers. PCR conditions were as described in Section 4.2.2. Library
cleanup was performed by adding a Clean Up buffer (39% 5M NaCl, 31.25% of 40% PEG 8000, 29.75%
molecular-grade water) to AMPure XP beads before combining it with the PCR-amplified sample.
Ethanol washing and sample eluting were performed as described above in Section 4.2.2.
4.2.5. MBM Urine Processing for HTG miRNA WTA
After nucleic acid isolation from melanoma patients’ urine samples (refer to Section 4.1.1), 35 ng of
RNA was loaded onto the HTG EdgeSeq instrument for WTA probe-capture. Samples were diluted in
HTG Lysis buffer or BioFluids Lysis buffer according to the manufacturer’s recommendations. Library
preparation and cleanup were as described in Section 4.2.4.
4.2.6. NGS Library Quality Check
All libraries were quantitated using the KAPA Library Quant Kit (Illumina Inc., San Diego, CA,
USA) and the Universal qPCR Mix Kit (Roche, Basel, Switzerland) according to the manufacturer’s
recommendations. Quality check (QC) for library size was performed on the Agilent Technologies
TapeStation 2200 instrument using the High Sensitivity D1000 ScreenTape and High Sensitivity D1000
reagents (Agilent Technologies Inc., Santa Clara, CA, USA). The expected peak size was between
150 and 170 base pairs. Samples that did not indicate proper library formation were excluded from
sequencing and repeated for library preparation.
4.2.7. NGS Library Normalization and Pooling
Quantitated libraries were diluted, normalized, and pooled according to the protocol generated
by the HTG EdgeSeq RUO Library calculator software version 2.0.0. Libraries were denatured in
2 N NaOH for 8 min at RT. NaOH was hydrolyzed with 2 N HCl and the denatured pool was diluted
down to 20 pM with the HT1 buffer supplied in the MiSeq V3 Kit (Illumina Inc., San Diego, CA, USA).
To introduce sequencing diversity and a positive sequencing control, 12.5 pM PhiX Control v3 library
(Illumina Inc., San Diego, CA, USA) was spiked into the diluted and denatured 20 pM sample pool.
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The final pool was made to be 95% sample libraries and 5% PhiX control by concentration. The pooled
library was then denatured at 98 ◦C for 4 min and immediately placed on ice for at least 5 min before
loading it onto the Illumina HiSeq 2500, MiSeq, or NextSeq 550 instruments according to the respective
Illumina instrument sequencing protocols.
4.2.8. NGS Profiling of the Libraries
Sequencing with Illumina platforms was conducted according to HTG instructions. Sequences
were assessed with a read length of 1 × 50 base pairs. FASTQ files were generated from raw sequencing
data using Illumina BaseSpace BCL to FASTQ software version 2.2.0 and Illumina Local Run Manager
Software version 2.0.0. FASTQ files were analyzed with HTG EdgeSeq Parser software version
v5.1.724.4793 to generate raw counts for 2083 miRs per sample.
4.2.9. HTG NGS Arrays
The HTG miRNA WTA was run on a 96-well HTG plate configuration for the normal donors’
plasma and serum samples, while the melanoma patients’ plasma samples were run on a 24-well
HTG plate configuration. Each HTG miRNA WTA includes negative (CTRL_ANT1, CTRL_ANT2,
CTRL_ANT3, CTRL_ANT4, CTRL_ANT5) and positive (CTRL_miR_POS) miR controls that are
included in the 2083 total miR panel. In all runs, Human Brain Total RNA (Ambion, Inc., Austin,
TX, USA) was used as a control for library preparation, but they were not sequenced. To test the
reproducibility of the HTG miRNA WTA, the normal donors’ plasma and serum patients’ samples were
run twice on the HTG EdgeSeq instrument and subsequently sequenced to check for reproducible results.
4.3. Biostatistical Analysis
The DESeq2 data subgroup normalization, analyses, and statistical comparisons in: (1) Normal
serum versus normal donors’ plasma; (2) MBM-01 plasma versus normal donors’ plasma; (3) MBM-02
versus normal donors’ plasma; (4) MBM01-02 plasma versus MBM tissue; (5) MBM-01 plasma versus
LuBM plasma; (6) MBM-01 plasma versus BCBM plasma; (7) MBM-01 plasma versus GBM plasma; and
(8) melanoma CII-treated pre- and post-treatment plasma versus normal donors’ plasma; (9) melanoma
CII-treated pre- and post-treatment urine versus normal donors’ urine were all performed using the
HTG REVEAL software version: 2.0.1. Box plot and t-test analysis were performed with GraphPad
prism 5 (GraphPad software Inc., La Jolla, CA, USA). Data processing and analysis were performed
using Python 3.7.4 in Jupyter platform [56]. MicroRNA expression counts were logarithmically scaled
(log10) for data visualization. PCA and data normalization were performed using Scikit-learn open
source Python library version 0.22.1 [57] to signify miRNA expression profiles. Matplotlib package
version 3.1.3 was utilized for making 2D plots in the python environment [58]. Hierarchically clustered
heatmaps were generated using Seaborn version 0.10.1. NumPy library version 1.18.1 [59] and SciPy
library 1.4.1 version [60] were utilized to process data matrices. AUC calculation was performed
with the SPSS software program, ver. 25.0 (IBM Inc., Chicago, IL, USA). A two-sided p-value < 0.05
was considered statistically significant: * p < 0.05; ** p < 0.01; *** p < 0.001 and NS = non-significant.
The figures were made using CorelDraw graphics suite 8X (Corel Corporation, Ottawa, ON, Canada).
4.4. Data Deposit
The data generated and discussed in this pilot study has been deposited in the National Center
for Biotechnology Information’s Gene Expression Omnibus (GEO) and is accessible through the GEO
Series accession number GSE150956.
5. Conclusions
There is an urgent need to identify robust cfmiR biomarkers that are detectable in body fluid
biopsy assays. We have provided a comprehensive analysis (Graphical abstract) using different
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cohorts of MBM, LuBM, BCBM, and GBM tumors. The results demonstrated how specific cfmiR
signatures distinguished MBMs from other types of brain cancer metastases as well as primary GBMs.
Moreover, cfmiR detection can potentially be used to monitor melanoma patients undergoing CII
therapy. Specific cfmiRs identified in MBMs overlapped with melanoma patients receiving CII. A urine
cfmiR assay was developed to demonstrate the detection of cfmiRs and its potential in assessing
melanoma patients receiving CII. Our results showed the potential utility of the HTG miRNA WTA
and the cfmiR signatures detected in plasma and urine samples for monitoring metastatic melanoma
patients’ progression and treatment.
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